vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.
SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $19.1M, roughly 1.3× NewAmsterdam Pharma Co N.V.). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs -90.7%, a 98.2% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 14.8%). SIFCO INDUSTRIES INC produced more free cash flow last quarter ($8.0M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.
NAMS vs SIF — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $24.0M |
| Net Profit | $-17.4M | $1.8M |
| Gross Margin | — | 21.6% |
| Operating Margin | -186.1% | 10.7% |
| Net Margin | -90.7% | 7.5% |
| Revenue YoY | 740.1% | 14.8% |
| Net Profit YoY | 55.5% | 177.3% |
| EPS (diluted) | $-0.15 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $24.0M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | $19.1M | $22.1M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | $12.8M | $20.9M | ||
| Q3 24 | $29.1M | $21.7M | ||
| Q2 24 | — | $22.0M | ||
| Q1 24 | — | $20.5M |
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-429.0K | ||
| Q2 25 | $-17.4M | $3.4M | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | $-92.2M | $-2.3M | ||
| Q3 24 | $-16.6M | $-443.0K | ||
| Q2 24 | — | $72.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | 12.3% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | -1.7% | ||
| Q2 25 | -186.1% | 14.8% | ||
| Q1 25 | — | -4.1% | ||
| Q4 24 | -338.5% | -9.2% | ||
| Q3 24 | -85.9% | -1.5% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | -6.5% |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | -1.9% | ||
| Q2 25 | -90.7% | 15.4% | ||
| Q1 25 | — | -7.3% | ||
| Q4 24 | -721.7% | -11.1% | ||
| Q3 24 | -57.2% | -2.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | -7.8% |
| Q4 25 | — | $0.29 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | $-0.15 | $0.56 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | $-0.91 | $-0.38 | ||
| Q3 24 | $-0.18 | $-0.07 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $1.1M |
| Total DebtLower is stronger | — | $39.0K |
| Stockholders' EquityBook value | $778.5M | $38.7M |
| Total Assets | $815.1M | $74.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $491.0K | ||
| Q2 25 | $739.2M | $2.0M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | $834.2M | $3.1M | ||
| Q3 24 | $422.7M | $1.7M | ||
| Q2 24 | — | $3.4M | ||
| Q1 24 | — | $2.5M |
| Q4 25 | — | $39.0K | ||
| Q3 25 | — | $51.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | — | $38.7M | ||
| Q3 25 | — | $36.9M | ||
| Q2 25 | $778.5M | $35.8M | ||
| Q1 25 | — | $32.4M | ||
| Q4 24 | $757.5M | $33.7M | ||
| Q3 24 | $378.9M | $30.4M | ||
| Q2 24 | — | $29.8M | ||
| Q1 24 | — | $29.7M |
| Q4 25 | — | $74.9M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | $815.1M | $77.3M | ||
| Q1 25 | — | $78.8M | ||
| Q4 24 | $864.6M | $81.0M | ||
| Q3 24 | $439.2M | $104.6M | ||
| Q2 24 | — | $106.3M | ||
| Q1 24 | — | $104.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $8.1M |
| Free Cash FlowOCF − Capex | $-37.8M | $8.0M |
| FCF MarginFCF / Revenue | -197.2% | 33.3% |
| Capex IntensityCapex / Revenue | 0.5% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 4.51× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.1M | ||
| Q3 25 | — | $726.0K | ||
| Q2 25 | $-37.7M | $371.0K | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | $-37.5M | $-3.8M | ||
| Q3 24 | $-12.5M | $857.0K | ||
| Q2 24 | — | $382.0K | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | — | $8.0M | ||
| Q3 25 | — | $566.0K | ||
| Q2 25 | $-37.8M | $310.0K | ||
| Q1 25 | — | $2.7M | ||
| Q4 24 | $-37.5M | $-3.9M | ||
| Q3 24 | $-12.6M | $580.0K | ||
| Q2 24 | — | $-175.0K | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | 33.3% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | -197.2% | 1.4% | ||
| Q1 25 | — | 14.1% | ||
| Q4 24 | -293.5% | -18.8% | ||
| Q3 24 | -43.2% | 2.7% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | -18.9% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | 4.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.31× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
SIF
| Fixed Wing Aircraft Revenue | $10.5M | 44% |
| Commercial Revenue | $8.7M | 36% |
| Commercial Product And Other Revenue | $2.8M | 12% |
| Commercial Space | $1.1M | 5% |
| Other | $840.0K | 4% |
